Baird Medical Successfully Concludes Gynecology Microwave Ablation Masterclass

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) concluded a Gynecological Microwave Ablation Masterclass in Shanghai on January 28, 2026, led by Dr. Xiaoming Gong. The program combined didactic lectures and live case observations to train physicians across Asia in the company's proprietary microwave ablation technology.

The event reinforces Baird Medical's focus on physician education, expansion of minimally invasive women's health treatments, and broader commercial presence, noting FDA 510(k) certification and use in over 30 U.S. hospitals and in more than 20 countries.

News Market Reaction – BDMD

+6.86%

4 alerts

+6.86% Session close to close

+8.4% Peak Tracked

$42.60M Market Cap

1.0x Rel. Volume

In the Jan 28 session, BDMD gained 6.86%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.4% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.9% in the session following this news. A strong positive reaction aligns with BDM...

Analysis

The stock moved +6.9% in the session following this news. A strong positive reaction aligns with BDMD’s pattern of constructive responses to expansion and regulatory milestones, as seen after approvals in Pakistan and Vietnam and the U.S. manufacturing announcement, which posted gains of up to 3.88%. However, the stock traded about 87.69% below its 52-week high before this news, and a sizable registered resale overhang of 70.9% could add supply pressure that might temper the durability of large spikes.

Key Figures

Warrant shares registered: 11,500,000 shares Resale registration: 34,415,562 shares Warrant exercise price: US$11.50 per share +5 more

8 metrics

Warrant shares registered 11,500,000 shares Ordinary shares issuable upon exercise of public warrants at US$11.50

Resale registration 34,415,562 shares Ordinary shares registered for resale by existing shareholders

Warrant exercise price US$11.50 per share Exercise price for public warrants

Reference share price US$1.63 Nasdaq share price cited as of December 4, 2025

Resale share proportion 70.9% Resale shares as portion of outstanding on assumed conversions

U.S. hospital footprint Over 30 hospitals and clinics U.S. institutions using Baird Medical solutions

Country reach Over 20 countries Commercial presence of minimally invasive treatment products

Current share price $1.02 Pre-news trading level vs 52-week range $0.9903–$8.2888

Historical Context

5 past events · Latest: Jan 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 26	Strategic partnership	Positive	+0.0%	Partnership with Stonewood Key Capital to accelerate global MWA commercialization.
Jan 20	Conference engagement	Positive	-0.9%	Strategic meetings at J.P. Morgan Healthcare Conference on 2026 growth priorities.
Jan 07	Regulatory approvals	Positive	+3.9%	Product registrations in Pakistan and Vietnam supporting Southeast Asia expansion.
Dec 17	Manufacturing expansion	Positive	+2.2%	Establishment of U.S. manufacturing base via MPS Medical partnership.
Dec 08	Clinical training	Positive	-4.9%	Advanced MWA training for an Arizona surgeon with live procedures and planning.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Operational and expansion updates are generally positive, with three prior news events seeing aligned price gains and two showing negative or selling reactions despite constructive headlines.

Recent Company History

Recent BDMD news has focused on global expansion and clinical adoption. On Dec 8, 2025, advanced MWA training in Arizona supported U.S. thyroid adoption. A U.S. manufacturing base announcement on Dec 17, 2025 and new registrations in Pakistan and Vietnam on Jan 7, 2026 advanced its global footprint. Participation at the 2026 J.P. Morgan Healthcare Conference and the Jan 26, 2026 Stonewood Key Capital partnership reinforced commercialization priorities, with mixed short-term price reactions.

Key Terms

microwave ablation, 510(k), warrants, ordinary shares, +1 more

5 terms

microwave ablation medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology"

Microwave ablation is a medical procedure that uses focused microwave energy to heat and destroy abnormal tissue, such as tumors, through a needle-like probe inserted into the body; think of it as using a tiny, targeted microwave oven to cook away problem cells without large incisions. It matters to investors because it represents a growing category of minimally invasive treatments that can reduce hospital stays, create demand for specialized devices and disposables, and influence reimbursement and adoption trends in healthcare markets.

510(k) regulatory

"As an FDA 510(k)-certified medical device company, Baird Medical's solutions"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

warrants financial

"ordinary shares issuable upon exercise of public warrants at US$11.50 per share"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

ordinary shares financial

"ordinary shares issuable upon exercise of public warrants at US$11.50 per share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

hfCAA regulatory

"warns that HFCAA-related auditor inspection issues could eventually lead to a Nasdaq delisting"

The HFCAA is a U.S. law that requires companies listed on U.S. stock exchanges to allow their auditors to be inspected by U.S. regulators; if a company’s auditors can’t be reviewed for several years, the company risks being removed from U.S. markets. For investors, it matters because the law increases transparency and audit oversight—think of it as a safety inspection for a car—while also creating a clear regulatory trigger that can affect a stock’s availability and price if compliance can’t be shown.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Jan. 28, 2026  /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful conclusion of its Gynecological Microwave Ablation Masterclass in Shanghai. Led by Dr. Xiaoming Gong of Weheal, the program offered a rigorous curriculum designed to advance procedural expertise in the treatment of benign gynecological conditions using the Company's proprietary technology.

The event featured a combination of expert-led didactic lectures and live case observations, providing participating physicians from across Asia with critical insights into clinical applications and techniques. By focusing on both theoretical knowledge and practical application, the Masterclass reinforced the importance of precision in clinical practice and facilitated the exchange of advanced methodology among regional specialists.

This initiative highlights Baird Medical's enduring commitment to physician education and the expansion of minimally invasive treatment options for women's health. Through programs like the Shanghai Masterclass, the Company continues to empower medical professionals with the skills necessary to deliver superior patient outcomes using state-of-the-art microwave ablation therapy.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-successfully-concludes-gynecology-microwave-ablation-masterclass-302669438.html

SOURCE BDMD

FAQ

What was taught at Baird Medical's Gynecological Microwave Ablation Masterclass in Shanghai (BDMD) on Jan 28, 2026?

The Masterclass taught procedural technique and clinical application of microwave ablation for benign gynecological conditions. According to the company, the curriculum combined expert lectures and live case observations to advance physician skills across Asia.

Who led the BDMD Gynecology Masterclass in Shanghai and which physicians attended?

Dr. Xiaoming Gong led the Shanghai Masterclass attended by physicians from across Asia. According to the company, participants included regional specialists focusing on minimally invasive gynecological procedures using the company's technology.

How does the BDMD Masterclass support Baird Medical's strategy and market presence?

The Masterclass supports physician education and product adoption in Asia, aligning with commercial expansion goals. According to the company, it demonstrates commitment to training clinicians on proprietary microwave ablation therapy to improve patient outcomes.

Is Baird Medical's microwave ablation technology FDA cleared and used in U.S. hospitals?

Yes. Baird Medical's devices are FDA 510(k) certified and reported as used in over 30 U.S. hospitals. According to the company, notable hospitals include Mayo Clinic and UCSF Medical Center among others.

Will the Shanghai Masterclass change BDMD's product availability or regulatory status?

The Masterclass is educational and does not change regulatory status or immediate product approvals. According to the company, the event aims to broaden clinical expertise and support adoption of existing FDA 510(k)-cleared solutions.

How does the Masterclass impact physicians and patient care using BDMD technology?

The program aims to improve procedural precision and clinical outcomes through hands-on training and live observation. According to the company, the curriculum emphasized practical techniques to enhance minimally invasive treatment options in women's health.